1841464-21-8
1841464-21-8
Chemical Structure
K-Ras-PDEδ-IN-1
- CAS No.: 1841464-21-8
- Formula:C25H26FN5O2
- Molecular Weight:447.50
IUPAC Name: N-(4-fluorophenethyl)-4-(4-methyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)butanamide
InChIKey: RRELLHHWESTKAK-UHFFFAOYSA-N
SMILES: O=C(NCCC1=CC=C(F)C=C1)CCCN2N=C(C)C3=CN(C4=CC=C(C)C=C4)N=C3C2=O
Biological Activity: K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
K-Ras-PDEδ-IN-1 | 99.45% | K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deltazinone 1 | 98.79% | Deltazinone 1, a pyrazolopyridazinone, is a highly selective PDEδ inhibitor with a KD of 8 nM. Deltazinone 1 inhibits the PDEδ-Ras interaction. Deltazinone 1 shows a dose-dependent inhibitory response on proliferation in oncogenic KRas-dependent cell lines. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
APP-FUBINACA | APP-FUBINACA is a cannabinoid receptor agonist and a derivative of phenylalaninamide-based indazole-3-carboxamide. APP-FUBINACA exhibits neurostimulatory effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
P-gp/BCRP-IN-1 | P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of P-gp and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TLR9-IN-1 | 99.67% | TLR9-IN-1 is a potent and selective TLR9 inhibitor with an IC50 value of 7 nM for human TLR9. TLR9-IN-1 can be used for researching diseases associated with undesirable immune response. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PDEδ autophagic degrader 1 | PDEδ autophagic degrader 1 (compound 12c), an autophagosome-tethering compound (ATTEC). is a potent PDEδ autophagic degrader. PDEδ autophagic degrader 1 reduces the PDEδ protein level through lysosome-mediated autophagy without affecting the PDEδ mRNA expression. PDEδ autophagic degrader 1 suppresses the growth in KRAS mutant pancreatic cancer cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ZIKV-IN-8 | ZIKV-IN-8 (Compound 9b) is a noncompetitive Zika virus (ZIKV) inhibitor. ZIKV-IN-8 shows the best anti-ZIKV activity with a selectivity index of 22.4. ZIKV-IN-8 has significant inhibition of ZIKV with an IC50 value of 25.6 μM. ZIKV-IN-8 can be used for the research of ZIKV infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pexmetinib (Standard) | ≥98% | Pexmetinib (Standard) (ARRY-614 (Standard)) is the analytical standard of Pexmetinib (HY-16782). This product is intended for research and analytical applications. Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PSB-22219 | PSB-22219 is a highly selective non-nucleotidic ligand acting on P2Y12 receptors (KD=4.57 nM). PSB-22219 is promising for research of P2Y12 receptor-associated neuroinflammation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PDEδ-IN-1 | PDEδ-IN-1 is the ligand of PDEδ. PDEδ-IN-1 can be used to synthesize PDEδ autophagic degrader 1 (HY-157458). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D18024 | D18024 is a phthalazinonderivat antiallergic and antihistaminic activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
